Urologic Oncology: Seminars and Original Investigations
Review articleHeterogeneity in renal cell carcinoma
Introduction
Renal cell carcinoma (RCC) accounts for approximately 4% of all new cancer cases worldwide, accounting for more than 90% of primary kidney tumors [1]. Despite the increased rate of incidental renal masses, 15% to 20% of cases are discovered at an advanced stage [2]. Targeted therapy based on common molecular alterations has become first-line therapy for patients with advanced RCC [1], [3]. However, most patients will eventually develop resistance [3].
Intratumor heterogeneity (ITH) at the genetic level is defined as the presence of genetically different clones in different subpopulations of the same tumor [4]. RCC is known to be a heterogeneous tumor, and ITH in RCC had been demonstrated over two decades ago [5]. Several studies have shown the existence of ITH among primary and metastatic lesions by identifying the differences in the rates of von Hippel-Lindau gene (VHL) mutations and copy number changes of other chromosomes [6], [7]. These differences at the genomic level is a key mechanism in the differential response to pharmacotherapy and treatment resistance.
Section snippets
Methods
A comprehensive search of MEDLINE/PubMed was performed to find basic science, review, and original articles in English language until November 2016. No other limit was placed on dates of publication. The keywords to identify articles of interest included but were not limited to RCC, kidney cancer, heterogeneity, ITH, intertumor heterogeneity, renal mass biopsy, and targeted therapy. Articles were identified by searching the title of the article using “and” statements such as “renal cell
Genomic mutations and tumorigenesis in RCC
There are well-established genetic mutations that cause the various subtypes of RCC. These include mutations of the VHL gene, which occurs in most patients with clear cell RCC (ccRCC) [8]. MET and fumarate hydratase mutations have been associated with papillary RCC (pRCC). Mutations in folliculin are associated with chromophobe RCC (chRCC), whereas TFEB/TFE3 genes translocation mediates translocation RCC (tRCC). Hereditary cases make up only 4% of patients with RCC. This low incidence means
Conclusion
RCC is a highly heterogeneous tumor. Therefore, a single treatment option cannot be the preferred treatment for all patients. Current evidence suggests that treatment resistance and failure is caused by resistant subclones that are not targeted by the initial treatment. This could be addressed by combination therapies. However, a one-size-fits-all approach is not optimal for treating advanced RCC and treatments need to be personalized. Better sampling of tumor specimens and identification of
References (66)
- et al.
Evaluation of the clonal relationship between primary and metastatic renal cell carcinoma by comparative genomic hybridization
Am J Pathol
(1999) - et al.
Unique molecular alteration patterns in von Hippel-Lindau (VHL) gene in a cohort of sporadic renal cell carcinoma patients from Pakistan
Mutat Res
(2014) - et al.
The roles of chromatin-remodelers and epigenetic modifiers in kidney cancer
Cancer Genet
(2015) - et al.
Intratumoral morphologic and molecular heterogeneity of rhabdoid renal cell carcinoma: challenges for personalized therapy
Mod Pathol
(2015) - et al.
Dissecting cancer evolution at the macro-heterogeneity and micro-heterogeneity scale
Curr Opin Genet Dev.
(2015) - et al.
Clonal evolution in breast cancer revealed by single nucleus genome sequencing
Nature
(2014) - et al.
ClearCode34: a prognostic risk predictor for localized clear cell renal cell carcinoma
Eur Urol
(2014) - et al.
The PI3K/AKT pathway and renal cell carcinoma
J Genet Genomics
(2015) - et al.
The somatic genomic landscape of chromophobe renal cell carcinoma
Cancer Cell
(2014) - et al.
Multi-quadrant biopsy technique improves diagnostic ability in large heterogeneous renal masses
J Urol
(2015)
Cancer evolution: the final frontier of precision medicine?
Ann Oncol
Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial
Lancet Oncol
Kidney cancer, version 3.2015
J Natl Compr Canc Netw
Molecular genetics of clear-cell renal cell carcinoma
J Clin Oncol
Targeted-therapy in advanced renal cell carcinoma
Curr Med Chem
Intratumor heterogeneity: evolution through space and time
Cancer Res
Comparison of flow cytometric, static cytometry and tumor cytogenetic investigation results human renal cell carcinomas
Verh Dtsch Ges Pathol
Differing von hippel lindau genotype in paired primary and metastatic tumors in patients with clear cell renal cell carcinoma
Front Oncol
Comprehensive molecular characterization of clear cell renal cell carcinoma
Nature
SETD2 loss-of-function promotes renal cancer branched evolution through replication stress and impaired DNA repair
Oncogene
How should clinicians address intratumour heterogeneity in clear cell renal cell carcinoma?
Curr Opin Urol
Intra-tumor heterogeneity of cancer cells and its implications for cancer treatment
Acta Pharmacol Sin
Microenvironmental regulation of tumor progression and metastasis
Nat Med
Tumor-derived microvesicles in the tumor microenvironment: how vesicle heterogeneity can shape the future of a rapidly expanding field
Bioessays
Regulatory T cells in the tumor microenvironment and cancer progression: role and therapeutic targeting
Vaccines
NK cells in the tumor microenvironment
Crit Rev Oncog
PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma
Clin Cancer Res
Cancer stem cells and the tumor microenvironment: interplay in tumor heterogeneity
Connect Tissue Res
Correlation of PD-L1 tumor expression and treatment outcomes in patients with renal cell carcinoma receiving sunitinib or pazopanib: results from COMPARZ, a randomized controlled trial
Clin Cancer Res
Ultra-deep T cell receptor sequencing reveals the complexity and intratumour heterogeneity of T cell clones in renal cell carcinomas
J Pathol
Differential expression of PD-L1 between primary and metastatic sites in clear-cell renal cell carcinoma
Cancer Immunol Res
Cells of origin in cancer
Nature
The causes and consequences of genetic heterogeneity in cancer evolution
Nature
Cited by (83)
Advanced in vitro models for renal cell carcinoma therapy design
2023, Biochimica et Biophysica Acta - Reviews on CancerThe emerging genetic landscape of renal cell carcinoma
2023, Diagnostic Molecular Pathology: A Guide to Applied Molecular Testing, Second EditionManagement of Renal Cell Carcinoma: Promising Biomarkers and the Challenges to Reach the Clinic
2024, Clinical Cancer Research